These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 26032514

  • 1. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [Abstract] [Full Text] [Related]

  • 2. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [Abstract] [Full Text] [Related]

  • 3. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
    Fonseca R, Rajkumar SV.
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):315-7. PubMed ID: 18854289
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Takeda Y, Sakaida E, Nakaseko C.
    Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
    [Abstract] [Full Text] [Related]

  • 5. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G.
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
    Zou Y, Lin M, Sheng Z, Niu S.
    Leuk Lymphoma; 2014 Sep; 55(9):2024-31. PubMed ID: 24067138
    [Abstract] [Full Text] [Related]

  • 7. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
    Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B.
    Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
    [Abstract] [Full Text] [Related]

  • 8. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E.
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [Abstract] [Full Text] [Related]

  • 9. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP, Chen SL.
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [Abstract] [Full Text] [Related]

  • 10. Multiple myeloma.
    Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.
    Lancet; 2009 Jul 25; 374(9686):324-39. PubMed ID: 19541364
    [Abstract] [Full Text] [Related]

  • 11. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M, Tani C, Kaichi Y, Sakoda Y, Kiguchi M, Date S, Kuroda Y, Sakai A, Awai K.
    Clin Lymphoma Myeloma Leuk; 2014 Dec 25; 14(6):485-92. PubMed ID: 25190250
    [Abstract] [Full Text] [Related]

  • 12. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC.
    Eur J Haematol; 2012 May 25; 88(5):446-9. PubMed ID: 22300348
    [Abstract] [Full Text] [Related]

  • 13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A, Attal M, Roussel M.
    Clin Cancer Res; 2011 Mar 15; 17(6):1253-63. PubMed ID: 21411441
    [Abstract] [Full Text] [Related]

  • 14. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X, Sun WJ, Chen SL, Zhong YP, An N, Hu Y, Zhang JJ, Liu XH.
    Zhonghua Yi Xue Za Zhi; 2012 Mar 27; 92(12):838-41. PubMed ID: 22781459
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.
    J Clin Oncol; 2010 May 01; 28(13):2259-66. PubMed ID: 20368561
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.
    Expert Rev Anticancer Ther; 2008 Jul 10; 8(7):1053-72. PubMed ID: 18588451
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.
    Lancet Oncol; 2010 Oct 10; 11(10):934-41. PubMed ID: 20739218
    [Abstract] [Full Text] [Related]

  • 19. Pomalidomide for multiple myeloma.
    Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S, Facon T, Leleu X.
    Expert Rev Hematol; 2014 Dec 10; 7(6):719-31. PubMed ID: 25265911
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J.
    Leuk Res; 2014 Sep 10; 38(9):1048-54. PubMed ID: 25052306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.